NCT02329314

Brief Summary

Collect the details about hepatic dysfunctional patients induced by various etiology who have a usage of Glycyrrhizic Acid, then arrange and analyse the data to evaluate the clinical curative effect of glycyrrhizic acid.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2014

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2014

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 26, 2014

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 31, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2016

Completed
Last Updated

December 31, 2014

Status Verified

December 1, 2014

Enrollment Period

1.6 years

First QC Date

December 26, 2014

Last Update Submit

December 30, 2014

Conditions

Liver Damage

Outcome Measures

Primary Outcomes (1)

  • Biochemical indexes measured before and after the interference

    to measure biochemical indexes such as ALT, AST, ALB, TBiL, et al before and after the interference with Glycyrrhizic Acid

    1-4 weeks

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

This experiment will screen and collect qualified casefrom medical records in Shuguang Hospital.to collect the patients with liver injury in clinic, including (1) conforms to ALT\>1.5 times the normal value or \>70IU/L, age 18 to 70 years of age, sex is not limited; (2) patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ; (3) except for tumor patients.

You may qualify if:

  • conforms to ALT\>1.5 times the normal value or \>70IU/L, age 18 to 70 years of age, sex is not limited;
  • patients with viral hepatitis or cirrhosis of the liver, or autoimmune liver disease, or schistosomiasis, or drug-induced liver damage, or for other reasons clear or unclear leading to abnormal liver function ;

You may not qualify if:

  • patients with tumor;
  • pregnant or lactating women, and pregnancy may not take effective contraceptive measures;
  • complicated with serious heart, lung, gallbladder, kidney, endocrine, hematopoietic system and mental disease;
  • the researchers think that should not be selected for this test.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shuguang Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Central Study Contacts

Wu Chao, postgraduate

CONTACT

1522109520215221095202@163.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
postgraduate

Study Record Dates

First Submitted

December 26, 2014

First Posted

December 31, 2014

Study Start

November 1, 2014

Primary Completion

June 1, 2016

Study Completion

June 1, 2016

Last Updated

December 31, 2014

Record last verified: 2014-12

Locations

CN(1)